Uveal melanoma, a type of cancer that develops in the back of the eye, is usually treated with surgery or radiation therapy. About half of all uveal melanomas come back in another part of the body. In this study, researchers want to evaluate the safety and effectiveness of the drug crizotinib in patients with uveal melanomas that have been treated with surgery or radiation therapy but have a high risk of coming back.
Crizotinib is already approved for treating a type of lung cancer, but its use for uveal melanoma is considered investigational. Laboratory studies show that crizotinib can kill uveal melanoma cells. It is a pill that is taken orally (by mouth).